FDA Accepts Supplement for GADAVIST by Bayer Healthcare
The FDA has accepted a supplemental application for GADAVIST, a gadobutrol-based contrast agent.
Asset / Drug
Drug and asset intelligence for GADAVIST with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.